Agoracom Blog Home

Posts Tagged ‘Diagnos Inc’

Empower Clinics $CBDT.ca $EPWCF Secures Medical Device Establishment Licence (MDEL) Status To Sell KAI Saliva COVID-19 PCR Test Kits In Canada $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:05 AM on Wednesday, February 10th, 2021
  • Announced it has secured Medical Device Establishment Licence (“MDEL”) status to sell its KAI Medical COVID-19 Saliva Test kits (“KAI Saliva”).
  • KAI Saliva is FDA EUA approved for use, has CE Mark and the saliva specimen collection device is approved by Health Canada.
  • KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into to Canada or arriving to other countries that have similar executive travel orders.

VANCOUVER BC / February 10, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce it has secured Medical Device Establishment Licence (“MDEL”) status to sell its KAI Medical COVID-19 Saliva Test kits (“KAI Saliva”).

KAI Saliva is FDA EUA approved for use, has CE Mark and the saliva specimen collection device is approved by Health Canada. KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into to Canada or arriving to other countries that have similar executive travel orders.

EMPOWER ACCELERATES ABILITY TO DISTRIBUTE AND SELL MEDICAL DEVICE PRODUCTS IN CANADA THROUGH PARTNERSHIP WITH MEDIPRO CANADA

Empower previously announced the filing of an MDEL application for the purpose of importing, distributing and selling KAI Saliva, which has experienced success upon its launch.

To accelerate the process, Empower partnered with MediPro Canada Inc. (“MediPro”) to utilize their approved MDEL status. MediPro provides healthcare products for governments, large corporations and medical facilities around the world and is led by Hon. Sheila Maureen Copps PC OC.

“We continue to see extensive demand for novel COVID-19 testing products in both private sector and public sector markets throughout North America, Mexico and Caribbean countries.” said Hon. Sheila Copps OC, Partner MediPro Canada. “Leveraging the vast network of MediPro Canada with the integrated healthcare capabilities of Empower Clinics and their novel COVID-19 testing products, makes for an ideal partnership.”

“We all have an urgent requirement for a home-based, self-administered COVID-19 saliva test kit that can help open up the economy and facilitate travel that meets the requirements of the executive travel orders.” said Steven McAuley, Chairman & CEO. “We also must utilize our resources, our reach, our capability, do everything we can to assist, be humanitarians, use our voice, strive to provide improved healthcare, and lead the path of progressive healthcare.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/755072-empower-clinics-secures-medical-device-establishment-licence-mdel-status-to-sell-kai-saliva-covid-19-pcr-test-kits-in-canada/messages/2303015#message

Empower $CBDT.ca $EPWCF Partners with #Rexall $MCK To Launch Integrated Healthcare Centres $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 12:26 PM on Tuesday, February 9th, 2021

Partnership Accelerates Empower’s Strategy To Execute National Healthcare Centre Expansion By Bringing Accessible and Progressive Primary Care and Para-Medical Care to Millions of Canadians

  • Announced effective February 8, 2021 a partnership with Rexall Pharmacy Group to launch the first of multiple integrated healthcare centres within Rexall pharmacies commencing in Ontario, Canada.
  • Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.

VANCOUVER, BC / February 9, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce effective February 8, 2021 a partnership with Rexall Pharmacy Group to launch the first of multiple integrated healthcare centres within Rexall pharmacies commencing in Ontario, Canada.

“In our first press release of 2021 announcing the closing of our Canadian Clinics acquisition, I stated Empower had a winning business model with immediate expansion plans throughout Greater Toronto, followed by Ontario and then nationwide with at least 30 clinics in rapid succession. Empower is proud to begin delivering on that promise.” said Steven McAuley, Chairman & CEO. “To say this is the Company’s biggest announcement in its history would not be an over statement. This partnership with Rexall accelerates our nationwide healthcare expansion strategy, I look forward to bringing Six Sigma philosophies and continuous process improvements to our operations to ensure customers and our patients have access to our primary care and para-medical services for years to come. Today marks a major win for Canadian healthcare and the shareholders of Empower Clinics.”

PARTNERSHIP IDENTIFIES INITIAL LOCATIONS IN ONTARIO

Rexall and Empower have identified numerous initial locations throughout Ontario, spanning from Ottawa to London and around the GTA. The size of the locations can range from 1,500 to 4,000 square feet. As each new location is agreed upon, key terms are outlined in a letter of intent and in the lease or sub-lease agreements with the first anticipated agreements February 2021.

HEALTH CARE SERVICES TO BE DELIVERED

Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.

Primary care services include:

  • Family physicians
  • Walk-in physicians
  • Tele-medicine and virtual care

Paramedical services include:

  • Chiropractic
  • Physiotherapy
  • Registered Massage Therapy
  • Chiropody
  • Acupuncturists
  • Osteopaths
  • Nutritionists

ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED

Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include:

  • Dermatology
  • Cardiology

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/754999-empower-partners-with-rexall-r-to-launch-integrated-healthcare-centres/messages/2302856#message

Empower Clinics $CBDT.ca $EPWCF Subsidiary KAI Medical Laboratory Awarded #COVID-19 Testing & Healthcare Management Program for Five Million Square Foot Dallas Market Center, The Most Complete Wholesale Trade Resource in The World With $8 Billion USD In Annual Transactions $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:05 AM on Monday, February 1st, 2021

  • Awarded a long-term COVID-19 testing and healthcare management program for the Dallas Market Center, the leading wholesale marketplace in North America and the most complete wholesale trade resource in the world.
  • DMC is a five million square foot, global business-to-business trade center and the leading wholesale marketplace in North America connecting retailers and interior designers with top manufacturers in home décor, furniture, gifts, lighting and fashion.

VANCOUVER BC / February 1, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (EPWCF:OTCQB) (8EC:Frankfurt) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens each month, developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce that KAI Medical Laboratory has been awarded a long-term COVID-19 testing and healthcare management program for the Dallas Market Center (“DMC”), the leading wholesale marketplace in North America and the most complete wholesale trade resource in the world.

KAI TO PROVIDE DAILY ONSITE COVID TESTING TO KEEP FIVE MILLION SQUARE FOOT TRADE CENTER OPEN TO BUYERS AND SELLERS FROM AROUND THE WORLD

DMC is a five million square foot, global business-to-business trade center and the leading wholesale marketplace in North America connecting retailers and interior designers with top manufacturers in home décor, furniture, gifts, lighting and fashion. DMC markets events throughout the year attracting buyers and sellers from all 50 states and more than 80 countries, resulting in significant economic impact:

  • $8 Billion in annual wholesale transactions
  • $1.1 Billion in indirect local economic impact
  • $380 million in direct local economic impact

“We cannot recover from crises like the COVID-19 pandemic without a resilient retail sector and the market centers have a critical role in participating in that recovery,” said Harlan Crow, chairman of the company that owns DMC in a January 3, 2021 Forbes Article.

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/754316-empower-clinics-subsidiary-kai-medical-laboratory-awarded-covid-19-testing-healthcare-management-program-for-five-million-square-foot/messages/2301340#message

VIDEO – Empower Clinics $CBDT.ca $EPWCF CEO Answers Shareholder Questions In First Ever Shareholder Q&A $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 9:20 PM on Thursday, January 21st, 2021

On behalf of Steve and the Empower Clinics team, we are happy to present the first ever Empower Clinics Shareholder Q&A.  

Thanks to all investors that posted their questions here on AGORACOM and on Twitter.

Enjoy this video with Steve from an undisclosed location that he reveals during the interview.

Empower Clinics $CBDT.ca $EPWCF Doubling KAI Medical Laboratory Size In Anticipation Of Test Volumes By End Of Q1. Files MDEL Application With Health Canada To Import and Sell KAI Saliva PCR Test In Canada $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:58 AM on Thursday, January 21st, 2021

  • Announced significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.
  • In addition, Empower has filed a Medical Device Establishment Licence with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test, which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.

VANCOUVER, BC / January 21, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.

In addition, Empower has filed a Medical Device Establishment Licence (“MDEL”) with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test (“KAI Saliva”), which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.

KAI MEDICAL LABORATORY EXPANDING TO AT LEAST DOUBLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED GROWTH IN VOLUME

KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI experienced significant growth in its first quarter under Empower, with Q4 COVID-19 test kit volumes exceeding 6,000 units, far surpassing the 1,300 total units prior to acquisition.

Current run rate projections now indicate as follows:

  • January 2021 is expected to exceed 8,000 tests, surpassing all of Q4 2020
  • February 2021 could see daily rates hit 1,000 tests per day
  • March 2021 could see daily rates hit 2,000 tests per day

These run rates DO NOT include the recent 25,000 unit order for KAI Saliva test kits, nor do they include any test kits from the launch of KAItests.com

Empower Clinics CEO, Steven McAuley stated “Our investment in R&D is really starting to pay off for KAI Medical, starting with a new state-of-art laboratory information system to automate processes for the anticipated growth in volume. Next, we have hired three new scientists, increased administrative staff and are activating a call center to provide world-class customer support. Further, the investment in new test protocols such as the Kai Saliva test kit, combined with our Health Canada medical device licence, positions us to be a leader in the reactivation of travel for Canadians.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/753555-empower-clinics-doubling-kai-medical-laboratory-size-in-anticipation-of-test-volumes-by-end-of-q1-files-mdel-application-with-health-canada-to/messages/2299214#message

Empower Clinics $CBDT.ca $EPWCF Announces First Ever AGORACOM Video Q&A with Shareholders Submitting Questions for Direct Response by CEO Steven McAuley $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:47 AM on Tuesday, January 19th, 2021

Shareholders are able to submit questions by either:

  • Posting directly to the Empower Verified Forum on AGORACOM at https://agoracom.com/ir/EmpowerClinics/forums/discussion and checking the “?” box
  • Posting on Twitter to both @EmpowerClinics and @Agoracom with the any of the following hashtags #empowerclinics_QA, #CBDTQA, #CBDT_QA

Questions must be posted by no later than Wednesday, January 20th, 5PM EST.

With Empower Clinics Entering Growth Phase On Multiple Business Fronts, Chairman & CEO Steven McAuley Provides Shareholders With An Opportunity To Fully Participate In Company’s First AGORACOM Video Q&A

VANCOUVER, BC / January 19, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical clinics in USA and Canada, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce its first ever AGORACOM Video Q&A, which provides investors with the opportunity to submit questions for response by Chairman & CEO Steven McAuley.

Empower Clinics CEO Steven McAuley stated “With so much tremendous progress taking place for our company, as we head into what I expect to be our breakthrough and greatest year ever in 2021, I want to make sure shareholders have an opportunity to ask questions, receive answers directly from me and begin the process of regular engagement through our Verified Forum on AGORACOM. I am looking forward to engaging with shareholders and followers on the interview.”

VIDEO Q&A DETAILS

Shareholders are able to submit questions by either:

  • Posting directly to the Empower Verified Forum on AGORACOM at https://agoracom.com/ir/EmpowerClinics/forums/discussion and checking the “?” box
  • Posting on Twitter to both @EmpowerClinics and @Agoracom with the any of the following hashtags #empowerclinics_QA, #CBDTQA, #CBDT_QA

Questions must be posted by no later than Wednesday, January 20th, 5PM EST.

Read more: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/753351-empower-clinics-announces-first-ever-agoracom-video-q-a-with-shareholders-submitting-questions-for-direct-response-by-ceo-steven-mcauley/messages/2298759#message

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Sells Out First 5,000 Units Of FDA EUA Approved Saliva #COVID-19 Test Kits. Issues Order For Next 25,000 KAI Saliva PCR Test Kits With Sales Value Of $5.5M. Discussions With Major Airlines Underway $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:44 AM on Thursday, January 7th, 2021

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas,TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and colleges

  • Announced the successful launch of our KAI Saliva PCR Test with our initial soft launch of 5,000 units sold out and the order of 25,000 additional units with a sales value of approximately $5,500,000.
  • Initial and overwhelming demand for KAI Saliva stemmed from our existing customers in film & television productions, the commercial sector, and concierge testing supported by Sun Valley Health in Arizona.
  • Given the early and significant success of KAI Saliva since its launch on December 15, 2020, Empower is extremely confident in the continued success of KAI Saliva with both existing and expanded commercial customers in this next run.

VANCOUVER, BC / January 7, 2021 / EMPOWER CLINICS INC. (CBDT:CSE)(8EC:Frankfurt)(EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce the successful launch of our KAI Saliva PCR Test (“KAI Saliva”) with our initial soft launch of 5,000 units sold out and the order of 25,000 additional units with a sales value of approximately $5,500,000.

INITIAL DEMAND FOR FIRST RUN KAI SALIVA CAME FROM EXISTING COMMERCIAL CUSTOMERS, INCLUDING FILM & TELEVISION PRODUCTIONS. DIRECT TO CONSUMER CHANNEL LAUNCH IMMINENT

Initial and overwhelming demand for KAI Saliva stemmed from our existing customers in film & television productions, the commercial sector, and concierge testing supported by Sun Valley Health in Arizona. Given the early and significant success of KAI Saliva since its launch on December 15, 2020, Empower is extremely confident in the continued success of KAI Saliva with both existing and expanded commercial customers in this next run.

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/752516-empower-clinics-kai-medical-laboratory-sells-out-first-5-000-units-of-fda-eua-approved-saliva-covid-19-test-kits/messages/2296434#message

VIDEO – Empower Clinics $CBDT.ca $EPWCF CEO Says 2021 Will Be A Big Year With ~ $6.8M In Cash, New Acquisition, Partnerships and Products $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 10:26 PM on Monday, December 21st, 2020

Sometimes, you just have to let the numbers speak for themselves.  With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that any small cap Health & Wellness company  would kill for … but then you add in that CBDT has now delivered growth in 5 (FIVE) successive financial reports (Q4, FY 2019, Q1, Q2 and Q3), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.

But he was far from done.

On November 13th Empower announced it’s newly acquired Kai Medical Laboratory Achieved Record Testing Volume Month in October and Has Already Signed Numerous New Contracts … and that was the day the markets finally discovered what we already knew.  Empower Clinics was a major player in the Health & Wellness space from the lab to the clinic.

But he was far from done.

Since that day Empower has made several announcements that grew the Company by several magnitudes again.  From record testing contracts to new products, partnerships (We see you Loop Insights $MTRX + SimpliFlying) and a $5.5 MILLION injection from warrant proceeds (that is now closer to $6.8M), McAuley was building the foundations of a health & wellness powerhouse.

And let’s not forget about the major acquisition of 7 Canadian clinics with an immediate plan to add another 30 clinics across the country with some potential major partners/

Finally, for all the new investors that have joined Empower in the last several weeks, McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive environment in recent history and turn it into significant growth through Q4 2020 and the foundations to turn it into a powerhouse over the next 3 years. 

If you MISSED Well Health and CloudMD, you really need to take a close look at Empower as the next great potential small cap health & wellness company.

Watch this amazing interview.

Empower Clinics $CBDT.ca $EPWCF Signs Definitive Agreement to Acquire Momentum Health With 7 Canadian Clinics. Begins Planning for Nationwide Rollout $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 4:16 PM on Thursday, December 17th, 2020

Acquisition Will Expand Company’s North American Footprint And Strengthen Vertical Integration From Patients To Laboratory, Strengthening Testing and Bubble Initiatives

  • Announced the execution of a definitive share purchase agreement dated December 16, 2020 to acquire Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc.
  • Momentum Health operates a network of medical clinics with a team of healthcare professionals who provide para-medical care by applying a holistic and hands-on approach working with patients to unlock potential well-being.
  • Key services include physiotherapy, chiropractic, massage therapy, traditional Chinese medicine, athletic therapy and others.
  • Acquisition will include two standalone wellness clinics and five new co-located clinics in the Greater Toronto Area of Ontario, Canada, with immediate access to in excess of 20,000 patients.

VANCOUVER, BC / December 17, 2020 / Empower Clinics (CSE:CBDT)(OTC PINK:EPWCF)(FRA:8EC) (the “Company” or “Empower”), an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA and Health Canada approval, is pleased to announce the execution of a definitive share purchase agreement dated December 16, 2020 (the “Agreement“) to acquire Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc. (collectively “Momentum Health“).

Steven McAuley, Chairman and CEO of Empower stated “The acquisition of Momentum Health will be a significant milestone for both Empower and its shareholders that we expect will provide Empower with a growing accretive business, as well as, a winning business model with plans for immediate expansion across the Greater Toronto Area, the province of Ontario and then nationwide in very rapid succession. It is anticipated that this immediate and rapid nationwide expansion plan will be made possible by combining the winning Momentum Health model with the financial, marketing and operational control resources already successfully deployed by Empower in building its US operations, including the successful win of a $1.2 million testing contract with a film and television studio within just 45 days of acquiring our KAI Medical Lab. Significant discussions are already underway with potential nationwide partners and we expect to have developments in the very near future.”

ACQUISITION INCLUDES 7 CLINICS IN GREATER TORONTO AREA WITH IMMEDIATE PLANS TO EXPAND “CLINIC-IN-CLINIC” MODEL ACROSS CANADA.

Momentum Health operates a network of medical clinics with a team of healthcare professionals who provide para-medical care by applying a holistic and hands-on approach working with patients to unlock potential well-being. Key services include physiotherapy, chiropractic, massage therapy, traditional Chinese medicine, athletic therapy and others. The full range of services can be viewed at www.momentumhealthclinic.com.

The acquisition will include two standalone wellness clinics and five new co-located clinics in the Greater Toronto Area of Ontario, Canada, with immediate access to in excess of 20,000 patients.

More importantly, it is expected that expansion will be at a very attractive and cost-effective model of opening “clinics-within-clinics” in which the Company proposes to partner with large care facilities to provide para-medical clinics inside the physical location of the primary care facility. This model results in a win-win for both Empower and the primary care facility partner as follows:

  • Substantially improved care for patients of the primary care facility
  • Significantly reduced start-up costs for Empower
  • Immediate access to the large patient base of the primary care facility
  • Immediate rental income for the primary care facility

With this proven winning model, the nationwide roll-out it is planned to commence immediately upon closing of the acquisition with expansion in the Greater Toronto Area, followed by expansion throughout Ontario and finally West through all Provinces with a standardized brand and technology platform.

Moreover, the acquisition includes incentives for the two Co-Founders of Momentum Health to open an additional 30 clinics across Canada.

CEO McAuley added “Having Dr. Rabinowitz and Dr. Tsimerman join me in leadership to rapidly expand Empower’s clinic footprint across Canada will be invaluable toward meeting our ambitious objectives.”

Momentum Co-Founder Dr. Robinowitz commented “Joining Empower provides us with the opportunity to scale an intricately designed health care model alongside the outstanding professionals currently on their team. This transaction will not only allow our current patients to have increased access to integrative care, we also strive to exponentially increase our patient base with strategic, nationwide expansion.”

Momentum Co-Founder Dr. Tsimerman commented “I am thrilled to be joining Empower Clinics with a shared vision of nationwide, truly integrative medical care based on patient – centric services. This unique opportunity allows us to provide an unparalleled patient experience and create a leading approach to modernized health care.”

TERMS OF ACQUISITION

Pursuant to the terms of the Agreement, Empower will pay the vendors of Momentum Health $275,000 cash at closing (including $44,648 to settle an outstanding debt of Momentum Health) with an additional $75,000 to be withheld as a holdback for adjustments, for an aggregate cash payment of $350,000. In addition, at closing, Empower will issue Dr. Jordan Rabinowitz and Dr. Aviv Tsimerman or their affiliates 5,128,204 common shares in the capital of Empower (at a deemed price of $0.0975 per share), 2,564,102 of which will be subject to contractual resale restrictions resulting in them being released quarterly from the date of closing in eight (8) equal instalments.

PERFORMANCE INCENTIVES TO OPEN 30 ADDITIONAL LOCATIONS

The acquisition also includes long-term performance incentives for Dr. Rabinowitz and Dr. Tsimerman. If, within 18 months from the closing date, the Company or its affiliates have opened and have operating an aggregate of ten (10) new clinic locations in Canada (“Milestone One”), each of Dr. Rabinowitz and Dr. Tsimerman shall be entitled to receive incentive stock options of Empower to purchase 1,875,000 common shares of Empower, vesting as follows:

  1. 1/3 immediately;
  2. 1/3 upon of the Company or its affiliates having opened and operating an aggregate of twenty (20) new clinic locations in Canada; and
  3. 1/3 upon of the Company or its affiliates having opened and operating an aggregate of thirty (30) new clinic locations in Canada.

ADDITIONAL DETAILS

Empower has agreed to enter into employment agreements with Dr. Rabinowitz and Dr. Tsimerman on closing of the acquisition, to lead the Canadian clinic expansion strategy.

Completion of the acquisition contemplated by the Agreement is subject to customary closing conditions which the Company anticipates being completed on or before December 21, 2020.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the Company’s nationwide rollout and timing and results of such rollout; the Company expecting the acquisition will provide Empower with a growing accretive business, as well as, a winning business model with plans for immediate expansion across the Greater Toronto Area, the province of Ontario and then nationwide in very rapid succession; the Company’s expectation for the costs of expansion; and the Company’s plans to partner with large care facilities to provide para-medical clinics inside the physical location of the primary care facility and the results of such model. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Empower Clinics $CBDT.ca $EPWCF Announces Receipt of Over $5,500,000 From Exercise of Warrants, Launches New Corporate Website for Future Integrated Healthcare $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:32 AM on Monday, December 14th, 2020
  • Announce the receipt of in excess of $5,500,000 from the exercise of warrants up to December 11, 2020
  • The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company
  • It serves as an indication of the strength of Empower’s shareholder base and its following
  • Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond

VANCOUVER BC / December 14, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through its clinics, telemedicine platforms and as a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and validating novel COVID-19 testing protocols for CE, FDA and Health Canada approval is pleased to announce the following:

RECEIPT OF $5,500,000 + FROM THE EXERCISE OF WARRANTS ALLOWS EMPOWER TO CONTINUE TO EXECUTE WITH INCREASED STRENGTH

Empower is pleased to announce the receipt of in excess of $5,500,000 from the exercise of warrants up to December 11, 2020. The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company. It serves as an indication of the strength of Empower’s shareholder base and its following.

The Company expects to generate meaningful revenue from its current and anticipated sales pipeline over the next 12 months, as well as, receive additional proceeds from further anticipated warrant exercises, the Company is confident it has the war chest necessary to pursue numerous opportunities. KAI medical laboratory continues to expand nationwide in the U.S., Empower is growing physician services and direct access to patients through new clinics expansions and the company will provide dynamic technology-based healthcare services to meet patient needs.

Steven McAuley, Chairman and CEO of Empower stated, “The timing of these warrant exercises could not be better as we head into our biggest growth phase ever, thanks to rapidly growing demand for our KAI Medical Lab COVID-19 testing solutions, as well as, the impending launch of our FDA approved KAI Saliva Test plus the pending clinic group acquisition in Canada. These proceeds significantly bolster our financial strength, resources and confidence necessary to aggressively pursue our growth strategies in 2021.”

EMPOWER LAUNCHES NEW WEBSITE TO BETTER REFLECT COMPANY’S 2021 DIRECTION

The Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond, as well as, our defined vision as follows:

GROWTH PILLARS

Health & Wellness Is Our Purpose – Through our clinics in the US and telemedicine platform, our physicians treat patients in Oregon, Arizona and Washington State. Within this section you can read our statements about integrated care and patient first care.

Diagnostics & Tech Is Our Vision – The October 5th acquisition of Texas-based KAI Medical Laboratory was a significant achievement for Empower, as it firmly and immediately established the science and research side of Empower. In its first month, KAI delivered record revenues and soon after announced its first $1,000,000 COVID-19 testing contract for a major film and television studio.

This section is rich in information for investors that want to better familiarize themselves with the capabilities of KAI Laboratory and COVID-19 testing capabilities that attracted major contracts and R&D initiatives.

We invite all of our shareholders and prospective investors to visit our new website at https://www.empowerclinics.com/

EMPOWER TO COMMENCE VERIFIED DISCUSSIONS BY CEO AND KEY PERSONNEL ON AGORACOM

The Company is commencing discussions on its “CEO Verified Forum” on AGORACOM, which is intended to serve as one of the Company’s social media platforms for interaction with current and prospective shareholders.

Steven McAuley added “The growth experienced by Empower over the past 12 months has come from all sources providing the best possible engagement with our clients, followers, investors and all social platforms. I enjoy responding to shareholder inquiries, and the demand for engagement and discussion by investors has grown significantly. Engaging with Agoracom followers is an invaluable tool given our anticipated developments and I look forward to posting my comments and interactions with shareholders.”

The Empower Clinics Verified Forum can be found at https://agoracom.com/ir/EmpowerClinics/forums/discussion

About Empower

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients and provide long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

Dustin Klein
Director
[email protected]
720-352-1398

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.